Back to search results

Shared Decision Making for Atrial Fibrillation Treatment

This study is looking at a web-based tool to help Black and White adults with non-valvular atrial fibrillation (NVAF) make decisions about taking oral anticoagulation (blood thinners) to prevent strokes. The tool provides information on risks and benefits and helps understand your personal preferences. Researchers want to see if this tool helps more Black patients choose to use oral anticoagulation. You may be able to join if you are 18 or older, have NVAF, a CHA2DS2-VASc score of 2 or higher, and are new to starting oral anticoagulation. The study is currently unclear on its recruitment status.

Study design
This is a pilot study involving about 40 participants. It is designed to test if a patient decision support tool is practical and acceptable.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 12 months to measure study completion rates.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04956978

Shared Decision Making to Address Racial Disparities in Oral Anticoagulation in NVAF

Not Yet Recruiting
NAAges 18+InterventionalTreatment
Duke University
~40 participants
Updated 2026-09-09 on ClinicalTrials.gov
What's tested:Patient Decision Support Tool

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of patients willing to consent as measured by enrollment log
Measured over End of Study, 12 months
+4 more outcomes measured

Conditions

Atrial Fibrillation

Explore related trials

Atrial Fibrillation

NCT04956978

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Duke University Medical Center

    Durham, North Carolinano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Larry Jackson · PRINCIPAL_INVESTIGATOR · Duke University

Who to contact

Larry Jackson, MD
[email protected]
919-684-5948
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Black and White adults greater than or equal to 18 years of age
Clinical diagnosis of NVAF
CHA2DS2-VASc score greater than or equal to 2
New patient visit for initiation of oral anticoagulation at primary care and cardiology clinics

Exclusion

Unable to speak English
Unable to provide informed consent

What this trial measures

  • Proportion of patients willing to consent as measured by enrollment logEnd of Study, 12 months
  • Proportion of patients willing to participate as measured by enrollment logEnd of Study, 12 months
  • Rate of completion of questionnaire measures as measured by Research Electronic Data Capture (REDCAP)End of Study, 12 months

    Measured by RedCap (all questionnaires will be distributed through RedCap)

  • Rate of Patient Decision Support tool delivery and data capture as measured by web based data captureEnd of Study, 12 months
  • Percent of patients who stated that the intervention was acceptable as measured by patient and provider interviews.1 week post clinic visit